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Belgium.Meprin a and b, members of the astacin family of zinc metalloproteinases, are unique plasma mem-
brane and secreted proteases known to cleave a wide range of biological substrates involved in
inﬂammation, cancer and ﬁbrosis. In this study, we identiﬁed proMMP-9 as a novel substrate and
show that aminoterminal meprin-mediated clipping improves the activation kinetics of proMMP-
9 by MMP-3, an efﬁcient activator of proMMP-9. Interestingly, the NH2-terminus LVLFPGDL, gener-
ated by incubation with meprin a, is identical to the form produced in conditioned media from
human neutrophils and monocytes. Hence, this meprin-mediated processing and enhancement of
MMP-9 activation kinetics may have biological relevance in the context of in vivo inﬂammatory pro-
cesses.
Structured summary of protein interactions: Meprin beta cleavesMMP-9 by enzymatic study (View inter-
action)
Meprin beta cleaves MMP-9 by zymography (View interaction)
Meprin alpha cleaves MMP-9 by zymography (View interaction)
Meprin alpha cleaves MMP-9 by enzymatic study (View interaction)
 2012 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction complex promoter region and therefore is more subject to biolog-Gelatinase B or matrix metalloproteinase-9 (MMP-9, EC
3.4.24.35) is unique within the family of MMPs in terms of molec-
ular complexity as well as of biological regulation. The gene encod-
ing human MMP-9 is located on human chromosome 20 rather
than in the MMP gene cluster on human chromosome 11 [1]. The
protein contains an O-glycosylated domain between the catalytic
part and the hemopexin domain that yields highly ﬂexible and
elongated monomers and a unique molecular heterogeneity [2–
4]. In comparison with gelatinase A/MMP-2, MMP-9 has a morechemical Societies. Published by E
loprotease; CBB, coomassie
LRP, low-density lipoprotein
einase; OG, O-glycosylated;
en.be (G. Opdenakker).
hology, Biomedical Research
Building C, 3590 Diepenbeek,ical regulation [1,5].
MMP-9 is a proteolytic enzyme for which many substrates have
been deﬁned by in vitro tests, the most recent of which are de-
duced from degradomics analyses [6–8]. However, biological stud-
ies on the relevance of all these substrates, including extracellular
matrix molecules, is lagging behind biochemical studies. Therefore,
the deﬁnition of biological links between enzymes and substrates
will increase our understanding of MMP-9 functioning.
In a biological context, MMP-9 also interacts with molecules
different from substrates. These include the function-regulating
tissue inhibitors of metalloproteinases (TIMPs), cargo receptors
such as low-density lipoprotein receptor-related protein (LRP)-1
and LRP-2 that regulate the bioavailability of MMP-9 and cell sig-
naling receptors [3,9]. In many such cases, the hemopexin domain
is involved [2]. For instance, the group of Garcia-Pardo demon-
strated recently a non-catalytic role of the MMP-9 hemopexin do-
main in malignant B cell proliferation [10].
A third category of molecules that play a role in the biology of
MMP-9 are its activators. Like other MMPs, gelatinase B is a zymo-lsevier B.V. All rights reserved.
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that blocks the catalytic site through interaction with the Zn2+ ion.
This Cys-Zn2+ coordination confers latency to the pro-enzyme [11].
For a proMMP to become catalytically active, disruption of this
connection between the propeptide and the Zn2+ is required, a pro-
cess described as the cysteine switch mechanism [12]. Stepwise
activation by enzymes, including serine proteases and other MMPs,
has been linked into a network of interactions [1,13]. However, we
do not yet know which enzyme is a key player or which is the
prominent chain of interactions in any biological context. Stepwise
activation by stromelysin-1 or MMP-3 (EC 3.4.24.17) has been de-
scribed [14–16], as well as autocatalytic priming of the activation
in the presence of hemozoin, a crystalline detoxiﬁcation product
of heme formed in the food vacuole of malaria parasites during
hemoglobin digestion [17]. Proteolytic processing of the aminoter-
minus of MMP-9 is important for the activation by the cysteine
switch mechanism [12]. Other forms of processing have been de-
ﬁned, but no mechanism or enzyme has been implied. For instance,
we puriﬁed proMMP-9 from natural sources, including natural
MMP-9 from neutrophils or monocytes. In both these cases, the
experimentally derived aminoterminus was shorter than that
found in tumor cells [18–20] or that derived from the human
cDNA-derived sequence [21]. The proteases executing this amino-
terminal processing as well as the biological effects remained
elusive.
Intrigued by this enigma, we questioned whether MMP-9 func-
tionality could be modulated by the multidomain metalloendopep-
tidases meprin a and b (EC 3.4.24.18 and EC 3.4.24.63,
respectively). Recently, it was shown that meprins trigger the acti-
vation of proADAM (a disintegrin and metalloprotease)-10 [22]
and kallikrein 7 [23], and therefore might be generally important
for the maturation of other proteolytic enzymes. As members of
the metzincin superfamily of metalloproteinases, both meprinsFig. 1. Incubation with meprin a or b results in processing of proMMP-9. Recombinant
conditions for 1 hour at 37 C. Samples were collected and loaded onto 7.5% gelatin zym
486; (6) E/S = 1/1458; (7) E/S = 1/4374; (8) E/S = 1/13122; (9) proMMP-9 incubated in bu
indicated by white arrows. As a control, in panel (C) different concentrations of meprin
Lanes 1–4: meprin a at concentrations of 125 nM, 41 nM, 14 nM and 5 nM; lane 5, proM
concentrations of 125 nM, 41 nM, 14 nM and 5 nM; lane 10, proMMP-9 incubated with
independent experiments.were ﬁrst discovered as enzymes expressed in the kidney brush
border [24] and human small intestine [25]. Later on, it was shown
that meprins are also expressed in a variety of tissues including
brain, skin and lung [26–29]. Their release by leukocytes is re-
quired for efﬁcient migration through the extracellular matrix dur-
ing inﬂammatory conditions [30,31]. The highly glycosylated
meprins are the only subgroup of proteinases within astacins that
function both at the membrane and extracellularly, and they can
process biologically active peptides, cytokines, extracellular matrix
components and cell-surface proteins [29,32,33]. Meprin is a major
sheddase at the cell surface and in the pericellular space. Identiﬁed
substrates include interleukin-1b [34] interleukin-18 [35], epider-
mal growth factor [27], pro-collagen III [36], the vascular endothe-
lial growth factor A [37], the amyloid precursor protein [28,38] and
ADAM-10 [22]. A proteomic approach identiﬁed a variety of addi-
tional physiologically relevant meprin substrates [39]. Several
pathological situations are associated with altered meprin expres-
sion, including inﬂammatory bowel disease [40], nephritis [36,41]
and tumor progression [42,43].
Here we provide evidence that both meprin a and b are capable
of processing MMP-9. In addition, we show that aminoterminal
clipping of gelatinase B by meprins yields molecular forms that
are highly susceptible to activation by MMP-3, as compared to
the full length enzyme. We provide a molecular model with mech-
anistic insights how this processing may operate, for instance,
within an inﬂammatory context.
2. Materials and methods
2.1. Proteins and reagents
Recombinant human (rh) full-length proMMP-9 (rhproMMP-9,
92 kDa) was expressed in Sf9 insect cells and puriﬁed as previouslyhuman proMMP-9 was incubated with active meprin a (A) or b (B) at different E/S
ography gels. (1) E/S = 1/6; (2) E/S = 1/18; (3) E/S = 1/54; (4) E/S = 1/162; (5) E/S = 1/
ffer without meprin; (10) proMMP-9 not incubated. The cleaved MMP-9 forms are
a or b were analyzed for zymolytic activity in the absence of proMMP-9 substrate.
MP-9 incubated with meprin a at E/S = 1/6 for 1 h at 37 C; lane 6–9: meprin b at
meprin b at E/S = 1/6 for 1 hat 37 C. These zymographies are representative of 2
4266 N. Geurts et al. / FEBS Letters 586 (2012) 4264–4269described [3]. The following recombinant variant proteins were
generated by mutagenesis of full-length MMP-9 [3]: MMP-9DHem,
lacking the hemopexin domain (72-kDa); MMP-9DOG, lacking the
O-glycosylated (OG) domain (70-kDa) and MMP-9DOGHem, lack-
ing both the hemopexin and the OG domain (48-kDa). MMP-
9mutE, an inactive mutant (92-kDa) in which the catalytic Glu402
is mutated into Ala, was produced by in vitro mutagenesis in a sim-
ilar way as the MMP-9mutEC mutant, in which both the catalytic
Glu402 and Cys468 in the OG domain are mutated into Ala [3,17].
Rh active meprin a (80 kDa) and rh active meprin b (80 kDa) were
produced in insect cells and puriﬁed and activated as previously
described [26,44]. For the ﬂuorogenic gelatin assay, DQ™-gelatin
was purchased from Invitrogen (Carlsbad, CA, USA) and dissolved
in water at a ﬁnal concentration of 1 mg/ml (MM: 100,000
g/mol). In all experiments, DQ™-gelatin was used at a concentra-
tion of 2.5 lg/ml. For the incubation experiments as well as for
the DQ™-gelatin assay, assay buffer (20 mM Tris, 100 mM NaCl,
10 mM CaCl2, 0.01% Tween 20; pH 7.4) was used.Fig. 2. Differential cleavage pattern of proMMP-9 by meprin a and b as determined by
incubated at 37 C with meprin a or b at a E/S ratio of 1/16. At different time points aft
12.5% SDS-polyacrylamide gel loaded with 1 h incubation mixtures: (St) standard molec
inactive MMP-9 mutant; (4) inactive MMP-9 mutant + meprin a; (5) inactive MMP-9 m
This SDS–PAGE is representative of 2 independent experiments. (B) At different time p
Lanes 1 and 5: 1 h incubation with meprin a and meprin b, respectively; lanes 2 and 6: 2 h
with meprin a andmeprin b respectively; lanes 4 and 8: 10 h incubation with meprin a an
PAGE is representative of 2 independent experiments. The membrane fragments with th
used for Edman degradation analysis. (C) For each numbered MMP-9 fragment, the identi
human proMMP-9. Residues D-5PSSR are from the expression construct and the propepti
of the zinc-binding cysteine in red. Black vertical arrows show the cleavages by meprin2.2. Incubation of proMMP-9 with active meprin a or active meprin b
At an enzyme/substrate (E/S) ratio ranging from 1/6 to 1/13,000
with steps of a factor 3 (based on [36]), a constant concentration of
rh full-length proMMP-9 (92 kDa, 780 nM ﬁnal concentration) was
incubated with a decreasing concentration of rh active meprin a or
meprin b (starting from 125 nM to 0.06 nM) at 37 C in assay buf-
fer. After incubation, 0.3 ng MMP-9 of each sample was analyzed
by gelatin zymography (7.5% gels) as described previously [18].
As a control, different concentrations (ranging from 125 nM till
5 nM) of both active meprin a or b alone were analyzed by zymog-
raphy to test their zymolytic activity.
2.3. Peptide sequencing and identiﬁcation of cleaved fragments
Active rh meprin a or b (225 nM) was incubated at 37 C for
several periods of time (1 h, 2 h, 3 h, 10 h) with inactive rh proM-
MP-9 mutant (3.7 lM) substrate at an E/S ratio of 1/16. SamplesNH2-terminal sequence analysis. Recombinant inactive mutant of proMMP-9 was
er incubation, samples were collected and analyzed by SDS–PAGE. (A) CBB-stained
ular weight marker preparation (indicated in kDa); (1) meprin a; (2) meprin b; (3)
utant + meprin b. The cleavage fragments were boxed and each box was numbered.
oints after incubation, samples were collected and analyzed by SDS–PAGE (12.5%).
incubation with meprin a and meprin b, respectively; lanes 3 and 7: 3 h incubation
dmeprin b respectively. St, molecular weight standard (indicated in kDa). This SDS–
e cleaved segments of MMP-9, indicated in the numbered boxes, were excised and
ﬁed aminoterminal sequence is shown. (D) Aminoterminal sequence of recombinant
de of MMP-9 starts with A1PRQR and is here shown until residue 90, with indication
a, whereas the green arrows indicate aminoterminal cleavages by meprin b.
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onto a polyvinylidene diﬂuoride (PVDF) membrane by wet electro-
blotting. After Coomassie Brilliant Blue (CBB, 0.1%) staining, the
bands of truncated MMP-9 were excised and subjected to protein
sequencing by Edman degradation (Procise 491cLC, Applied
Biosystems).
2.4. Determination of MMP-9 activation velocity and activity with the
ﬂuorogenic DQ™-gelatin assay
Following the addition of active rh meprin a or b to rh proMMP-
9 or its mutants at an E/S of 1/16, the mixture was subjected to
activation by the catalytic domain of MMP-3 (MMP-3cd) at a molar
ratio of 1:100 (MMP-3: MMP-9) [3]. Samples were taken at differ-
ent time points (00; 100; 300; 600; 900, 120’; 2400, 3000) and analyzed
by zymography.
The activity was determined according to a published gelatino-
lytic assay [45]. Brieﬂy, following MMP-3cd activation, samples
containing 0.1 nM (for a ﬁnal volume of 100 ll) of the MMP-9 en-
zyme as well as control samples containing only meprin a or b or
MMP-3cd were added to a 96-well plate (Macro-assay plate (chim-
ney, 96-well, black, clear bottom), Greiner bio-one, Frickenhausen,
Germany). Subsequently, Dye-quenched (DQ)™-gelatin substrate
was added at a ﬁnal concentration of 2.5 lg/ml as optimized in
[45]. Immediately thereafter, the plate was placed in the ﬂuores-
cence reader (FL600 Microplate ﬂuorescence reader, Biotek, High-
land Park, IL, USA) and ﬂuorescence was measured every 10 min
for 2 h at 37 C (ex. 485 nm/em. 530 nm). In each experiment,
MMP-3 alone as well as active rh meprin a or meprin b were in-
cluded as control samples.
3. Results
To analyze whether proMMP-9 processing is triggered by mep-
rins, in vitro experiments were performed in which wild type hu-
man proMMP-9 and active meprin a or meprin b were incubatedFig. 3. ProMMP-9 activation velocity measurements. Meprin a (mep a) or meprin b (mep
(B), proMMP-9DOG (C) or proMMP-9DOGHem (D) and the MMP-3 catalytic domain w
incubation at 37 C, the resulting enzymatic activity was measured according to an optimat different physiological E/S ratios for one hour at 37 C. As shown
on gelatin zymography, incubation with meprin a (Fig. 1A) or b
(Fig. 1B) resulted in a concentration-dependent processing of proM-
MP-9 into lower molecular weight zymolytic bands and this was
not observed in the condition without meprin a or b. In addition,
processing of MMP-9 multimers also occurred in the presence of
meprin a or b. To investigate the gelatinolytic activity of both me-
prin a or b itself, different concentrations of the enzyme were ana-
lyzed by zymography. As shown in panel C of Fig. 1, no enzymatic
activity towards gelatin was detected in the samples containing dif-
ferent concentrations of only meprin a or b. Hence, the fragments
observed following zymography analysis ofMMP-9/meprin incuba-
tion samples (panel A and B and lane 5 panel C of Fig. 1) represent
meprin-mediated cleavage products derived from proMMP-9.
As a second approach, inactive rh proMMP-9 mutant, in which
the catalytic Glu402 is mutated into Ala, was incubated with meprin
a or b (E/S: 1/16) at 37 C. The use of an inactive mutant was rel-
evant to exclude autocatalysis of MMP-9. Panel A of Fig. 2 shows
the CBB-stained MMP-9 fragments derived from 1 h incubation
with meprin a or b. A similar pattern was observed after 10 hours
of incubation, although the stability of meprin awas reduced (data
not shown). At different time points after incubation, sample mix-
tures were separated by SDS–PAGE (12,5%) and after electroblot-
ting, the CBB-stained protein bands were excised and identiﬁed
by automated Edman degradation (Fig. 2B). The NH2-terminal se-
quence analysis indicates a differential cleavage pattern of proM-
MP-9 by meprin a or b (Fig. 2C), which is in line with the
already described different cleavage and substrate speciﬁcities of
both meprins [29]. Most of the cleavage sites are situated in the
propeptide of MMP-9 at locations ahead of the zinc ion-binding
cysteine residue at position 80 (Fig. 2D). However, considering
the low MW of speciﬁc cleaved fragments and the comparison of
zymography analysis in relation with CBB protein staining, we
demonstrated that also carboxyterminal cleavage of MMP-9 by
both meprin a and b took place. One cleavage site is identiﬁed in
the OG domain (band 7). It is interesting to note that the LVLFPGDLb) were simultaneously incubated with wild type proMMP-9 (A), proMMP-9DHem
as immediately added to the incubation mixture. At several time intervals after
ized gelatinolytic assay by using Quenched Dye-quenched (DQ)™-gelatin substrate.
Fig. 4. Model of meprin-mediated aminoterminal processing and disruption of the
propeptide-ﬁbronectin domain interaction. The dotted line shows the contours of
the 3-dimensional model of proMMP-9 monomers, as determined by Rosenblum
et al. [4]. FN, ﬁbronectin domain with three ﬁbronectin repeats; Hem, hemopexin
domain with a 4-blade propeller structure; OG, O-glycosylated domain; Zn2+, zinc
ion within the catalytic domain; Cys, cystein residue located at the carboxytermi-
nus of the propeptide; LRP-1/2, low-density lipoprotein receptor-related protein-1/
2. Meprin a or meprin b, symbolized here by black scissors, cleave 3–14
aminoterminal residues from the intact propeptide and thus relax the interactions
between the aminoterminal end of the propeptide and the ﬁbronectin domain. This
relaxation favors the further processing of the propeptide by MMP-3. The cleavage
by meprin in the hemopexin domain of MMP-9 may release the catalytic segment
from its cell-bound form and thus prevent intracellular uptake through the cargo
receptors LRP-1 and LRP-2.
4268 N. Geurts et al. / FEBS Letters 586 (2012) 4264–4269sequence as in band 1 and 2 is also identiﬁed as the NH2-terminal
sequence analysis of natural monocyte gelatinase (60%) and neu-
trophil gelatinase (30%) [18–20].
Incited by our previous work, by which we showed that prein-
cubation with synthetic hemozoin induced priming of MMP-9 acti-
vation by autocatalytic cleavages in the propeptide [17], we set up
a similar approach to investigate possible meprin-mediated inﬂu-
ences on MMP-9 activation kinetics by MMP-3. Mixtures of wild
type or mutant rh proMMP-9 forms (MMP-9DHem, MMP-9DOG
and MMP-9DHemOG) with meprin a or b (E/S: 1/16) were
subjected to activation by the catalytic domain of MMP-3
(MMP-3cd) at a molar E/S ratio of 1/100 [17]. Samples were taken
at different time points (00; 100; 300; 600; 900; 1200; 2400; 3000) and
analyzed by gelatin zymography (data not shown). The proteolytic
activity was determined according to an optimized gelatinolytic
assay by using Quenched Dye-Quenched (DQ)™-gelatin substrate
[45]. As shown in Fig. 3, the presence of meprin a or b enhanced
the activation kinetics of wild type and mutant proMMPs approx-
imately 3-fold. Indeed, 50% of the maximal MMP-9 activity was
reached within 30 minutes after incubation of proMMP-9 variants
with meprin a or b, whereas in the absence of meprin, the same
level of activity was achieved after roughly 100–160 min. The
priming of the activation was also obvious with the mutants lack-
ing the OG and/or Hem domains. This corroborates the ﬁndings
with the full-length MMP-9 and indicates that the meprin-induced
cleavages in the propeptide are responsible for the priming, and
not the cleavage in the OG domain (vide supra). The activity of
meprin a, meprin b or the MMP-3 cd against the DQ-gelatin
substrate was also checked and found to be negative.
4. Discussion
The mechanisms of proMMP-9 processing and activation in a
biological context are subject to much debate. In addition, we pre-
viously published that interaction of the MMP-9 hemopexin do-
main with synthetic hemozoin provokes autocatalytic
aminoterminal processing of the propeptide of MMP-9. This b-
hematin-mediated allosteric priming of proMMP-9 signiﬁcantly
enhanced the kinetics of its activation by the catalytic domain of
MMP-3 [17]. Here, we studied meprins, a subgroup of astacin zinc
metalloproteinases, as possible candidates in the MMP-9 activation
network. Two types of meprins exist, meprin a and meprin b,
which form disulﬁde-bonded homo- and heterodimers and further
oligomerization is mediated by non-covalent interactions
[44,46,47]. Both subunits are translated as proenzymes that have
to be activated by removal of an N-terminal propeptide [23,44,48].
Recently, meprins were used in a degradomics approach to un-
cover substrates and cleavage site speciﬁcities of both meprin a
and b [22,39]. Meprin subunits are capable of hydrolyzing a variety
of biologically active proteins and peptides. They may also cleave
many cytokines and chemokines, resulting either in degradation
or in an alteration in biological function/activity. One such example
is the processing by meprin a of proIL-1b into active IL-1b, as mea-
sured by an increased proliferative response of helper T-cells [34].
Furthermore, Banerjee et al. have identiﬁed proIL-18, a key cytokine
in the inﬂammatory response, as a biologically important substrate
of meprin b and they showed that hydrolysis results in a biologi-
cally active form of IL-18 [35]. In addition, the meprin b substrate
ﬁbroblast growth factor-19 was found to exhibit altered biological
activity on keratinocyte proliferation/migration after processing.
Parallel to these ﬁndings, we demonstrate in this work that process-
ing of MMP-9 by meprins results in altered proteolytic activity.
Indeed, meprins were found to process MMP-9 at both the amino-
and carboxyterminal ends and this truncation inﬂuenced the
activation process of MMP-9 by its well-known activator MMP-3.Meprin a and b exhibit strong preference for negatively charged
amino acids in P10 position, but might also accept other residues to
a lower extend [39]. This is also represented by the various NH2-
terminal variants identiﬁed in Fig. 2, where both meprins induced
a similar priming and enhancement of proMMP-9 activation.
Remarkably, the activation kinetics in the presence of meprins oc-
curred equally efﬁcient for both the wild type as well as the mutant
forms of MMP-9. This was in contrast to b-hematin-induced prim-
ing of proMMP-9, in which the hemopexin domain was essential
for interaction with the synthetic malaria pigment [17].
According to our data and based on the structural characteris-
tics of full-length proMMP-9 [4], we herein propose a model in
which, through aminoterminal clipping of a few amino acids, mep-
rins may disrupt the interaction of the propeptide with the ﬁbro-
nectin domain and this could ultimately facilitate the activation
by MMP-3 (Fig. 4). Furthermore, it is well-established that the
hemopexin domain mediates the catabolism of MMP-9 by interac-
tion with cargo receptors, e.g. LRP-1/2 [2,3]. Therefore, meprin-
induced cleavage in the OG-domain will lead to increased
half-lives and bio-availability. Such an effect would add up to
enhanced MMP-9 activities by the propeptide processing.
Interestingly, the predominant aminoterminus LVLFPGDL of the
proMMP-9 forms derived after truncation by meprin a (band 1 and
band 2 in Fig. 2 panel A and B) is identical to the major aminoter-
minal sequences of natural gelatinase B secreted by neutrophils
N. Geurts et al. / FEBS Letters 586 (2012) 4264–4269 4269and monocytes [18–20]. Hence, meprin a may be the natural pro-
cessing enzyme for neutrophil and monocyte-derived MMP-9 and
this truncation may prime propeptide processing, mediated by
MMP-3.
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